1. Home
  2. LVLU vs MRKR Comparison

LVLU vs MRKR Comparison

Compare LVLU & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lulu's Fashion Lounge Holdings Inc.

LVLU

Lulu's Fashion Lounge Holdings Inc.

N/A

Current Price

$13.64

Market Cap

36.8M

ML Signal

N/A

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.41

Market Cap

23.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LVLU
MRKR
Founded
1996
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.8M
23.0M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
LVLU
MRKR
Price
$13.64
$1.41
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$15.00
$11.25
AVG Volume (30 Days)
20.4K
121.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$315,887,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.53
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.81
52 Week High
$32.32
$4.07

Technical Indicators

Market Signals
Indicator
LVLU
MRKR
Relative Strength Index (RSI) 45.20 44.55
Support Level $13.19 $1.36
Resistance Level $16.25 $1.44
Average True Range (ATR) 1.05 0.11
MACD -0.18 -0.00
Stochastic Oscillator 28.50 18.92

Price Performance

Historical Comparison
LVLU
MRKR

About LVLU Lulu's Fashion Lounge Holdings Inc.

Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Share on Social Networks: